Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2015

01-09-2015 | Review

Malignant tumors of the uterine corpus: molecular background of their origin

Authors: D. Brany, D. Dvorska, M. Nachajova, P. Slavik, T. Burjanivova

Published in: Tumor Biology | Issue 9/2015

Login to get access

Abstract

Tumors of the uterine corpus can be divided into two main groups: endometrial tumors and mesenchymal tumors. The former ones are common gynecological diseases, whereas malignant mesenchymal tumors, which behave in a much more aggressive way, are quite rare with a poorer prognosis. The most common type of endometrial tumors is endometrioid adenocarcinomas, and in case of mesenchymal tumors, these are carcinosarcomas, or leiomyosarcomas, if only clear types of tumors are taken into account. The objective of this article is to review molecular-genetic abnormalities associated with tumorigenesis of both types of tumors, with focus on the most aggressive forms. This view includes a different expression pattern of genes, usually aberrant in cases of uterine cancer that can arise due to epigenetic modifications, mostly hypermethylation of promoters or microRNA (miRNA)’s interference with concrete genes. Furthermore, clinical predispositions of tumorigenesis, involving hormonal factors, age, and ethnicity, are also mentioned.
Literature
1.
2.
Zubor P, Kajo K, Stanclova A, et al. Human epithelial growth factor receptor 2 polymorphism and risk of fibroadenoma. Eur J Cancer Prev. 2008;17(1):33–8.CrossRefPubMed
3.
Galo S, Zubor P, Szunyogh N, et al. Sérové hladiny TNF u žien s endometriózou: prospektívna klinická štúdia. Ceska Gynekol. 2005;70(4):286–90.PubMed
4.
Culbova M, Lasabova Z, Stanclova A, et al. Metylácia vybraných tumor-supresorových génov v benígnych a malígnych ovariálnych nádoroch. Ceska Gynekol. 2011;76(4):274–9.
5.
Kudela E, Farkasova A, Visnovsky J. Amplification of 3q26 and 5p15 regions in cervical intraepithelial neoplasia. Acta Obstetrica Scandinav. 2014;93(10):s 997–1002.CrossRef
6.
Visnovsky J, Kudela E, Farkasova A, et al. Amplification of TERT an TERC genes in cervical intraepithelial neoplasia and cervical cancer. Neuroendocrinol Lett. 2014;35(6):518–22.PubMed
7.
Plataniotis G, Castiglione M. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:41–5.CrossRef
8.
Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009;16(1):8–13.PubMed
9.
Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol. 1984;64:417–20.PubMed
10.
Mortality for malignant tumors of the uterine corpus. American Cancer Society 2003; 98(1): 176–186.
11.
Oliver KE, Enewold LR, Zhu K, Conrads TP, Rose GS, et al. Racial disparities in histopathologic characteristics of uterine cancer are present in older, not younger blacks in an equal-access environment. Gynecol Oncol. 2011;123(1):76–81.CrossRefPubMed
12.
Kurman R, Norris H. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer. 1984;49:2547–59.CrossRef
13.
Fisher B, Costantino JP, Redmond CK, Fisher ER, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86(7):527–37.CrossRefPubMed
14.
Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;22:2304–10.CrossRef
15.
16.
Naumann RW. The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer. Gynecol Oncol. 2011;123:411–20.CrossRefPubMed
17.
Cheung LWT, Hennesy BT, Li J, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PteN protein stability. Cancer Discov. 2011;1(2):170–85.CrossRefPubMedPubMedCentral
18.
Markowska A, Pawałowska M, Lubin J, Markowska J. Signalling pathways in endometrial cancer. Contemp Oncol (Pozn). 2014;18(3):143–8.
19.
Llobet D, Pallarés J, Yeramian A, Santacana M, Eritja N, Velasco A. Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoint. J Clin Pathol. 2009;62:777–85.CrossRefPubMed
20.
Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, et al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One. 2012;7(2):e30801.CrossRefPubMedPubMedCentral
21.
Djordjevic B, Barkoh BA, Luthra R, Broaddus RR. Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas. Mod Pathol. 2013;26:1401–12.CrossRefPubMedPubMedCentral
22.
Segev Y, Iqbal J, Lubinski J, Gronwald J, et al. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol. 2013;130(1):127–31.CrossRefPubMed
23.
Hofmann WK, Takeuchi S, Takeuchi N, Thiel E, Hoelzer D, Koeffler HP. Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome. Leuk Res. 2006;30(11):1347–53.CrossRefPubMed
24.
Capper D, Gaiser T, Hartmann C, Habel A, et al. Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. Acta Neuropathol. 2009;117(4):445–56.CrossRefPubMed
25.
Zhou XC, Dowdy SC, Podratz KC, Jiang SW. Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment. Gynecol Oncol. 2007;107:143e53.CrossRef
26.
Banno K, Yanokura M, Susumu N, Kawaguchi M, Hirao N, Hirasawa A, et al. Relationship of aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. Oncol Rep. 2006;16:1189e96.
27.
Lai HC, Wang YC, Yu MH, Huang RL, Yuan CC, et al. DNA methylation as a biomarker for the detection of hidden carcinoma in endometrial atypical hyperplasia. Gynecol Oncol. 2014;135(3):552–9.CrossRefPubMed
28.
Fiolka R, Zubor P, Janusicova V, Visnovsky J, et al. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer. Oncol Rep. 2013;30:2878–86.PubMed
29.
Visnovsky J, Fiolka R, Kudela E, Slavik P, Krkoska M, Lasabova Z, et al. Hypermethylation of selected genes in endometrial carcinogenesis. Neuroendocrinol Lett. 2013;34(7):675–80.PubMed
30.
Arafa M, Kridelka F, Mathias V, Vanbellinghen JF, Renard I, Foidart JM, et al. High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma. Histopathology. 2008;53:525–32.PubMed
31.
Whitcomb BP, Mutch DG, Herzog TJ, Rader JS, Gibb RK, Goodfellow PJ. Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin Cancer Res. 2003;9:2277e87.
32.
Yang HJ, Liu VW, Wang Y, Tsang PC, Ngan HY. Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer. 2006;6:212.CrossRefPubMedPubMedCentral
33.
Sasaki M, Kaneuchi M, Sakuragi N, Dahiya R. Multiple promoters of catechol-O-methyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer. Cancer Res. 2003;63:3101e6.
34.
Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. 2007;104:15805e10.CrossRef
35.
Chung TK, Cheung TH, Huen NY, Wong KW, et al. Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer. 2009;124(6):1358–65.CrossRefPubMed
36.
Ramón LA, Braza-Boïls A, Gilabert J, Chirivella M, España F, et al. MicroRNAs related to angiogenesis are dysregulated in endometrioid endometrial cancer. Hum Reprod. 2012;27(10):3036–45.CrossRefPubMed
37.
Torres A, Torres K, Wdowiak P, Paszkowski T, Maciejewski R. Selection and validation of endogenous controls for microRNA expression studies in endometrioid endometrial cancer tissues. Gynecol Oncol. 2013;130(3):588–94.CrossRefPubMed
38.
Pfaffl MW, Tichopad A, Prgomet C, et al. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper–Excel-based tool using pair-wise correlations. Biotechnol Lett. 2004;26(6):509–15.CrossRefPubMed
39.
Tsukamoto O, Miura K, Mishima H, Abe S, et al. Identification of endometrioid endometrial carcinoma-associated microRNAs in tissue and plasma. Gynecol Oncol. 2014;132(3):715–21.CrossRefPubMed
40.
Giuntoli R, Metzinger DS, Dimarco CS, Cha SS, Sloan JA, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003;89:460–9.CrossRefPubMed
41.
Mehine M, Kaasinen E, Mäkinen N, Katainen R, Kämpjärvi K, Pitkänen E. Characterization of uterine leiomyomas by whole-genome sequencing. N Engl J Med. 2013;369:43–53.CrossRefPubMed
42.
Kämpjärvi K, Mäkinen N, Kilpivaara O, Arola J, Heinonen HR, Böhm J. Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer. Br J Cancer. 2012;107(10):1761–5.CrossRefPubMedPubMedCentral
43.
Bashir S, Jiang G, Joshi A, Miller Jr C, Matrai C, et al. Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors. Int J Gynecol Cancer. 2014;24(7):1262–7.CrossRefPubMed
44.
Livasy CA, Reading FC, Moore DT, Boggess JF. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol. 2006;100(1):101–6.CrossRefPubMed
45.
Rice LW, Stone RL, Xu M, Galgano M, Stoler MH, Everett EN, et al. Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors. Am J Obstet Gynecol. 2006;194(4):1119–26.CrossRefPubMed
46.
Skubitz KM, Skubitz APN. Differential gene expression in leiomyosarcoma. Cancer. 2003;98:1029–38.CrossRefPubMed
47.
Ünver NU, Acikalin MF, Öner Ü, Ciftci E, Ozalp SS, Colak E. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors. Arch Gynecol Obstet. 2011;284:483–90.CrossRefPubMed
48.
O’Neill CJ, McBride HA, Connolly LE, McCluggage WG. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumors of uncertain malignant potential. Histopathology. 2007;50:851–8.CrossRefPubMed
49.
Lee S, Kang DW, Hudgins-Spivey S, Krust A, et al. Theca-specific estrogen receptor-alpha knockout mice lose fertility prematurely. Endocrinology. 2009;150(8):3855–62.CrossRefPubMedPubMedCentral
50.
Kelley TW, Borden EC, Goldblum JR. Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study. Appl Immunohistochem Mol Morphol. 2004;12(4):338–41.CrossRefPubMed
51.
Koivisto-Korander R. Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers. Tumor Biol. 2011;32:451–9.CrossRef
52.
53.
Hayashi T, Horiuchi A, Sano K, et al. Mice-lacking LMP2, immuno-proteasome subunit, as and animal model of spontaneous uterine leiomyosarcoma. Protein Cell. 2010;1:711–7.CrossRefPubMedPubMedCentral
54.
Zaloudek CJ, Norris HJ. Mesenchymal tumors of the uterus. In: Fenoglio CM, Wolff M, editors. Progress in surgical pathology, vol. III. New York: Masson Publishing Inc.; 1981. p. 1–35.
55.
Philip PC, Cheung AN. Pathology of uterine leiomyosarcomas and smooth muscle tumors of uncertain malignant potential. Best Pract Res Clin Gastroenterol. 2011;25:691–704.
56.
Mittal K, Joutovsky A. Areas with benign morphologic and immunohistochemical features are associated with some uterine leiomyosarcomas. Gynecol Oncol. 2007;104:362–5.CrossRefPubMed
57.
Madhukar BM, Deshpande KA, Surase SG, Ajmera AP. Malignant transformation of leiomyoma of uterus to leiomyosarcoma with metastasis to ovary. J Obstetri Gynecol India. 2014;64:68–9.
58.
van Meurs HS. A uterine leiomyoma in which a leiomyosarcoma with osteoclast-like giant cells and a metastasis of a ductal breast carcinoma are present. Ann Diagn Pathol. 2012;16:67–70.CrossRefPubMed
59.
Mittal KR, Chen F, Wei JJ, Rijhvani K, Kurvathi R, Streck D, et al. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas. Mod Pathol. 2009;22:1303–11.CrossRefPubMed
60.
McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopatology. 2001;39:273–8.CrossRef
61.
Davidson B, Abeler VM, Hellesylt E, Holth A, Shih I, et al. Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma. Gynecol Oncol. 2013;128:349–55.CrossRefPubMed
62.
Cimbaluk D, Rotmensch J, Scudiere J, Gown A, Bitterman P. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol. 2007;105(1):138–44.CrossRefPubMed
63.
Atkins K, Bell S, Kempson M, Hendrickson M. Myxoid smooth muscle tumors of the uterus. Modern Pathol. 2001;132A:14.
64.
Growdon WB, Roussel BN, Scialabba VL, Foster R, Dias-Santagata D, Iafrate AJ, et al. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecol Oncol. 2011;121:212–7.CrossRefPubMed
65.
Jung CK, Jung JH. Diagnostic use of nuclear beta-catenin expression for the assessment of endometrial stromal tumors. Mod Pathol. 2008;21:756–63.CrossRefPubMed
66.
Davidson B, Abeler VM, Førsund M, Holth A, Yang Y, Kobayashi Y, et al. Gene expression signatures of primary and metastatic uterine leiomyosarcoma. Hum Pathol. 2014;45:691–700.CrossRefPubMed
67.
Chiang S, Ali R, Melnyk N, et al. Frequency of known gene rearrangements in endometrial stromal tumors. Am J Surg Pathol. 2011;35:1364–72.CrossRefPubMed
68.
Jour G, Scarborough JD, Jones RL, Loggers E, Pollack SM, Pritchard CC, et al. Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics. Hum Pathol. 2014;45:1563–71.CrossRefPubMed
69.
Seidel C, Bartel F, Rastetter M, Bluemke K, et al. Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. Int J Cancer. 2005;114(3):442–7.CrossRefPubMed
70.
Yin L, Cai WJ, Liu CX, Chen YZ, et al. Analysis of PTEN methylation patterns in soft tissue sarcomas by MassARRAY spectrometry. PLoS One. 2013;8(5):e62971.CrossRefPubMedPubMedCentral
71.
Chuang TD, Ho M, Khorram O. The regulatory function of miR-200c on inflammatory and cell-cycle associated genes in SK-LMS-1, a leiomyosarcoma cell line. Reproduct Sci. 2015;22:563–71. doi:10.​1177/​1933719114553450​.CrossRef
Metadata
Title
Malignant tumors of the uterine corpus: molecular background of their origin
Authors
D. Brany
D. Dvorska
M. Nachajova
P. Slavik
T. Burjanivova
Publication date
01-09-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3824-1

Other articles of this Issue 9/2015

Tumor Biology 9/2015 Go to the issue

Retraction Note

Retraction Note to: Prognostic value of CD133 expression in cancer patients treated with chemoradiotherapy: a meta-analysis

Erratum

Erratum to: Thioridazine specifically sensitizes drug-resistant cancer cells through highly increase in apoptosis and P-gp inhibition

Editorial

AdipoRon: a possible drug for colorectal cancer prevention?

Research Article

Role of Lgr5-positive cells in colorectal cancer

Research Article

JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression

Research Article

MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits